NASDAQ:ACRV • US0048901096
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACRIVON THERAPEUTICS INC (ACRV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-09 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-16 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-05-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-31 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-11-14 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | Ladenburg Thalmann | Upgrade | Neutral -> Buy |
| 2024-09-16 | BMO Capital | Reiterate | Outperform -> Outperform |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | BMO Capital | Reiterate | Outperform -> Outperform |
| 2024-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-29 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2024-04-26 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-04-25 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-04-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-04-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-05 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 805.34% | N/A 691.78% | N/A 321.81% | N/A 124.17% | N/A 57.34% | N/A 40.70% | N/A 41.31% | N/A 23.16% | ||||||
| EBITDA YoY % growth | -3.16M | -16.14M -410.76% | -32.3M -100.12% | -66.567M -106.09% | -88.193M -32.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.17M | -16.18M -410.41% | -32.66M -101.85% | -67.103M -105.46% | -89.199M -32.93% | N/A 6.56% | N/A -16.10% | N/A -34.23% | N/A -10.51% | N/A 21.39% | N/A 52.01% | N/A 206.10% | N/A 132.21% | N/A 40.17% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.73 60.91% | -2.44 10.62% | N/A 16.05% | N/A 5.32% | N/A 3.81% | N/A -4.84% | N/A 19.69% | N/A 47.40% | N/A 158.02% | N/A 270.21% | N/A 58.05% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.48 20.74% | -0.50 1.11% | -0.53 4.17% | -0.52 -11.61% | -0.58 -22.25% |
| Revenue Q2Q % growth | 169.024K | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.551M 13.64% | -22.503M -3.88% | -23.661M -4.47% | -25.058M -27.28% | -27.929M -29.59% |
All data in USD
15 analysts have analysed ACRV and the average price target is 11.73 USD. This implies a price increase of 671.71% is expected in the next year compared to the current price of 1.52.
ACRIVON THERAPEUTICS INC (ACRV) will report earnings on 2026-03-26, after the market close.
The consensus EPS estimate for the next earnings of ACRIVON THERAPEUTICS INC (ACRV) is -0.48 USD and the consensus revenue estimate is 169.02K USD.